Cellectis S.A.
cema-cel
large B-cell lymphoma (LBCL)
Countdown
724days
Phase 2 readout · ~ Jun 30, 2028 estimated
What's at stake
Phase 2 trial results for cema-cel in large B-cell lymphoma (LBCL) are due ~ Jun 30, 2028. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“Allogene announced that study accrual is anticipated to be complete by the end of 2027 and that it anticipates an interim Event-Free Survival (EFS) analysis in mid-2027 and the primary EFS analysis in mid-2028.”